Melanoma and Immunotherapy

Friday
October 8, 2021, 4:15 pm -
4:50 pm
Learning from a decade of success

Watch On Demand

Session Description

Immunotherapy has forever changed the way melanoma is treated. Checkpoint inhibitors, beginning with the landmark 2011 FDA approval of ipilimumab (Yervoy®), are responsible for the increasing survival rates for patients with metastatic melanoma. Join Dr. Margaret Callahan, a medical oncologist at Memorial Sloan Kettering Cancer Center, in a Q&A discussion about how immunotherapy is increasing survival rate for patients with metastatic melanoma and how doctors are bringing the benefits of immunotherapy to more melanoma patients.

Speaker(s)

Margaret Callahan, M.D., Ph.D.

Memorial Sloan Kettering Cancer Center

Dr. Margaret Callahan is a medical oncologist at Memorial Sloan Kettering Cancer Center (MSK), clinical director, Immune Monitoring, Parker Institute for Cancer Immunotherapy at MSK, and laboratory member in the Ludwig Center at MSK. Her research is focused on clinical and translational efforts to better understand the mechanisms that govern the clinical activity and toxicity associated with combination strategies for immunotherapeutic agents. She is involved in the research and development of novel immunotherapies to treat melanoma and other cancers, and the development of innovative approaches to monitoring patients treated with immunotherapy.

Moderator(s)

Sharon Belvin

Melanoma Veteran

In 2004, Sharon was diagnosed with stage 4 melanoma when she was just 22 years old. She started chemotherapy a few days before her wedding and experienced horrific side effects including neuropathy. She then switched to interleukin-2, which did not work and irritated her skin. Her oncologist, Dr. Jedd Wolchok at Memorial Sloan Kettering Cancer Center, told her about a new type of treatment called ipilimumab (Yervoy®) that “takes the brakes off” the immune system. She almost immediately agreed to enroll in the study. After only a few rounds of treatment, scans revealed that her tumors had shrunk by 60 percent. She has been in remission since. She is now a personal trainer and fitness instructor striving to help others on their health and fitness journeys, as well as a CRI ImmunoAdvocate spreading the word about immunotherapy.

On-Demand Now Available

We are excited to announce that videos from our 2021 Cancer Research Institute (CRI) Virtual Immunotherapy Patient Summit are now available to view on demand.

The on-demand videos can be found on each session page from the agenda.